Trial Profile

Assessment of Neointimal Stent Strut Coverage and Endothelial Function After Second Generation Drug-Eluting Stent Systems.

Status: Withdrawn prior to enrolment

Phase of Trial: Phase IV

Latest Information Update: 12 Apr 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Everolimus (Primary) ; Sirolimus (Primary) ; Zotarolimus (Primary)
Indications Coronary artery disease; Coronary artery restenosis
Focus Biomarker; Pharmacodynamics
Acronyms ASSESS

Most Recent Events

03 Aug 2018 Status changed from recruiting to withdrawn prior to enrolment.
06 Sep 2013 New source identified and integrated (University Hospital Medical Information Network - Japan; UMIN000003222).
06 Apr 2010 Trial acronym (ASSESS), long name and actual initiation date (Apr 2010) added as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com